ALFA Finder| Revenue growth | Broadly in line with FY25 at ₹3,744M. |
|---|---|
| Margins | EBITDA margins impacted by regulatory investments; projecting upper-teen margins post-remediation. |
| Demand visibility | Strong for NIP/OTF; $400M market opportunity for Dabigatran in Europe. |
| Management confidence | High; confident in EU GMP reinstatement following May 2026 inspection. |
Growth
FY26 revenue ₹3,744M; EBITDA ₹414M; PAT ₹58M. Q4 FY26 revenue ₹1,053M with 12.7% EBITDA margin.
Outlook
Guidance for mid-teen margins in FY27; expected commercialization of 17 NIP/OTF products within 24 months.
Risks
Geopolitical disruption in MENA caused ₹20-25cr impact; EU GMP compliance remains a critical dependency for regulated markets.
Earnings Call filed with NSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹141.00
- Market cap
- ₹756.6 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 365.3×Sector 43.8×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Investor Presentation: Key Takeaways
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.
- Key figure
- Net loss ₹2 Cr
Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.